Key insights
- H.C. Wainwright and Stifel reiterated Buy ratings on argenx (ARGX), with price targets of $940 and $1,255 respectively. Positive data for FcRn inhibitors, including argenx's Vyvgart, in rheumatology indications like myositis and Sjogren's disease, alongside strong revenue growth and upward earnings revisions, suggest potential upside. While Q1 earnings beat expectations, revenue slightly missed, indicating a mixed but generally positive outlook
Investing.com - H.C. Wainwright reiterated a Buy rating and $940.00 price target on argenx SE (NASDAQ:ARGX) on Thursday. The stock currently trades at $813.14, representing potential upside of approximately 16% to the analyst’s target.
The firm noted that at EULAR 2026, FcRn inhibitors continued to expand beyond neurology into rheumatology, further reinforcing the class’ potential across myositis, Sjogren’s disease, and SLE. Both argenx and Johnson & Johnson reported strong data across a range of indications.
Argenx reported the longest follow-up data for an FcRn inhibitor in myositis and Sjogren’s disease. Johnson & Johnson reported new exploratory analysis from the Phase 2 study of Sjogren’s disease and positive Phase 2 JASMINE data for SLE.
The data highlighted better performance of nipocalimab in patient populations with high baseline levels of disease-driven autoantibodies and in those with predefined autoantibodies, indicating a potential precision medicine for FcRn in rheumatic diseases. The safety profile of Vyvgart remains favorable across rheumatology indications.The company’s strong commercial momentum is reflected in its 79% revenue growth over the last twelve months, reaching $4.74 billion. According to InvestingPro analysis, argenx appears undervalued at current levels, with 10 analysts recently revising earnings upwards for the upcoming period.
Argenx plans to host a Myositis R&D webinar on June 23, 2026.
In other recent news, Argenx NV ADR reported its first-quarter earnings for 2026, surpassing analyst expectations with an earnings per share (EPS) of $5.52, compared to the forecast of $5.45. However, the company missed its revenue forecast, reporting $1.3 billion against the anticipated $1.32 billion. Despite the positive earnings surprise, the revenue shortfall has raised concerns among investors. Additionally, Stifel raised its price target on argenx SE to $1,255 from $1,222, while maintaining a Buy rating on the shares. The firm highlighted the importance of the upcoming Phase 3 data for the ALKIVIA study of efgartigimod in myositis, expected in the third quarter of 2026. Stifel also noted steady growth in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, although competition is increasing. These developments reflect ongoing investor interest and analyst attention in the company’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The best investments start with better data. Going with your gut has its place, but when excitement masquerades as intuition, it can lead to costly mistakes—or analysis paralysis. InvestingPro combines institutional-grade data with AI-powered insights that you don't need a finance PhD to understand. It won't guarantee winners, but it will certainly help you find more of them, more often. So what are the best investments of 2026 so far?